However, despite this, variable response rates to PARP inhibitors have been observed in patients with advanced germline BRCA1/2 mutation tumors, including those with ovarian cancer [3, 5, 6, 13, 14]. This evidence concerns the gene BRCA1 and ovarian cancer.